FDA Approves Blueprint Medicines ' Ayvakit (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
First precision therapy that specifically targets the primary driver of the disease
Durable clinical responses, including complete remissions, shown in patients with or without prior treatment
Full approval supported by robust efficacy and...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology